Personalis (NASDAQ:PSNL) Stock Rating Lowered by Wall Street Zen

Personalis (NASDAQ:PSNL) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other research firms have also issued reports on PSNL. Lake Street Capital reiterated a “buy” rating and issued a $11.00 target price on shares of Personalis in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd. Guggenheim lifted their price objective on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Morgan Stanley boosted their price objective on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Finally, HC Wainwright upped their target price on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Personalis presently has an average rating of “Moderate Buy” and a consensus target price of $11.14.

Personalis Stock Up 0.3%

Shares of PSNL opened at $9.06 on Friday. Personalis has a fifty-two week low of $2.83 and a fifty-two week high of $11.50. The firm’s 50 day moving average price is $8.83 and its 200 day moving average price is $7.96. The company has a market cap of $804.53 million, a P/E ratio of -9.96 and a beta of 1.98.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.05. The company had revenue of $17.35 million during the quarter, compared to analysts’ expectations of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 42.81%. Research analysts forecast that Personalis will post -1.4 earnings per share for the current year.

Hedge Funds Weigh In On Personalis

Hedge funds have recently added to or reduced their stakes in the stock. Deutsche Bank AG raised its holdings in Personalis by 4.5% during the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after purchasing an additional 1,655 shares in the last quarter. Royal Bank of Canada grew its position in shares of Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares during the last quarter. Howland Capital Management LLC raised its stake in Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after acquiring an additional 2,500 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Personalis by 184.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after acquiring an additional 3,592 shares in the last quarter. Finally, Intech Investment Management LLC lifted its position in Personalis by 23.4% in the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after acquiring an additional 3,851 shares during the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis News Roundup

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Analyst price-target upgrade — Needham raised its PSNL target from $10 to $12 and reiterated a “buy” rating, implying meaningful upside from the current price and signaling increased analyst confidence. Benzinga
• Positive Sentiment: Operational growth target — Management outlined a plan targeting ~170% clinical test-volume growth for 2026 and highlighted acceleration from reimbursement and its MRD (minimal residual disease) strategy, which, if realized, would drive revenue and margin scaling. Seeking Alpha: Clinical Test Volume Growth
• Positive Sentiment: Q4 outperformance vs. EPS estimates — Personalis reported a $0.26 loss per share, beating consensus by $0.05, and delivered revenue roughly in line to slightly above expectations, which supports the near-term stock uplift. Press Release / Q4 Results
• Neutral Sentiment: Earnings call and transcript available — Management commentary and the full Q4 2025 call transcript provide more color on reimbursement progress, MRD commercialization cadence and margin plans; these details will determine whether the growth targets are credible. Yahoo Finance: Q4 Earnings Call Transcript
• Neutral Sentiment: Media coverage / snapshot pieces summarize results and strategy but add little new detail beyond the company release and call. SeattlePI: Q4 Snapshot
• Negative Sentiment: FY2026 revenue guidance set below street expectations — Personalis guided to roughly $78–$80M for FY2026 versus a consensus near $81M, introducing downside risk to near-term estimates and valuation. Yahoo Finance: Full Year Results & Guidance
• Negative Sentiment: Elevated short interest and persistent losses — Short interest rose ~21% in February to ~12.5% of float (an 8.6-day ratio), while the company remains unprofitable with negative margins and ROE, increasing volatility and downside risk if execution slips. MarketBeat: Short Interest & Stock Data
• Negative Sentiment: Conflicting coverage on revenue beat/miss — Some outlets flagged a revenue miss while company/other reports show a slight revenue beat; this mixed narrative can amplify intraday moves as investors parse which data source is authoritative. Zacks: Q4 Loss / Revenue Comment

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.